

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter and without intention of creating any estoppel as to equivalents, as follows. Attached is a marked up version of the changes made by this amendment, captioned "Version With Markings to Show Changes Made."

In the Claims

Please amend the claims without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

3. (Amended) A method for producing an APC capable of inducing in a T cell tolerance to an allergen or antigen, which method comprises contacting an APC obtained from a human or animal patient with (i) a composition capable of upregulating expression of an endogenous Notch or Notch ligand in the APC and (ii) the allergen or antigen.

A' 4. (Amended) A method for producing *ex vivo* a T cell having tolerance to an allergen or antigen which method comprises incubating a T cell obtained from a human or animal patient with an antigen presenting cell (APC) in the presence of (i) a composition capable of upregulating expression of an endogenous Notch or Notch ligand in the APC and/or T cell and (ii) the allergen or antigen.

5. (Amended) The method according to any one of claims 1 to 4, wherein the composition comprises a substance capable of upregulating expression of Notch or a Notch ligand selected from polypeptides and fragments thereof, linear peptides, cyclic peptides, synthetic and natural compounds including low molecular weight organic or inorganic compounds.

6. (Amended) The method according to any one of claims 1 to 4, wherein the composition comprises a polypeptide selected from Noggin, Chordin, Follistatin, Xnr3, FGF and derivatives, fragments, variants and homologues thereof, and immunosuppressive cytokines, or a combination thereof.

8. (Amended) The method according to any one of claims 1 to 4 wherein the Notch ligand is selected from Serrate, Delta and homologues thereof.

A2 9. (Amended) The method according to any one of claims 1 to 4 wherein the APC is a dendritic cell.

10. (Amended) A method for producing a lymphocyte or APC having tolerance to an allergen or antigen which method comprises incubating a lymphocyte or APC obtained from a human or animal patient with a lymphocyte or APC produced by the method of any one of claims 1 to 4.

11. (Amended) A method for producing *ex vivo* a T cell having tolerance to an allergen or antigen which method comprises incubating a T cell obtained from a human or animal patient with a cell produced by the method of any one of claims 1 to 4.

12. (Amended) A method for suppressing an immune response in a mammal to an allergen or antigen comprising incubating a lymphocyte or APC obtained from a human or animal patient with (i) a composition capable of upregulating expression of Serrate or Delta in the lymphocyte or APC and (ii) the allergen or antigen and administering the lymphocyte or APC to the mammal.

Please add the following claims:

--19. (New) A method for producing a lymphocyte or antigen presenting cell (APC) having tolerance to an allergen or antigen, which method comprises incubating a lymphocyte or APC obtained from a human or animal patient with (i) a composition capable of upregulating expression of Serrate or Delta in the lymphocyte and/or APC and (ii) the allergen or antigen, wherein the lymphocyte is a T cell and the APC is a dendritic cell and wherein the composition comprises a polypeptide selected from the group consisting of Noggin, Chordin, Follistatin, Xnr3, FGF and immunosuppressive cytokines.

20. (New) The method of claim 19, wherein the allergen or antigen is selected from the group consisting of myelin basic protein, collagen, insulin, MHC antigens and Der p 1.

21. (New) A method for producing a lymphocyte or antigen presenting cell (APC) having tolerance to an allergen or antigen, which method comprises incubating a lymphocyte or APC with (i) a composition capable of upregulating expression of an endogenous Notch or Notch ligand in the lymphocyte and/or APC and (ii) the allergen or antigen.

22. (New) A method according to claim 21, wherein the method comprises incubating a lymphocyte or APC with an APC in presence of (i) a composition capable of upgrading expression of an endogenous Notch or Notch ligand in the lymphocyte and/or APC and (ii) the allergen or antigen.

23. (New) A method for producing an APC capable of inducing in a T cell tolerance to an allergen or antigen, which method comprises contacting an APC with (i) a composition capable of upregulating expression of an endogenous Notch or Notch ligand in the APC and (ii) the allergen or antigen.

24. (New) A method for producing a T cell having tolerance to an allergen or antigen which method comprises incubating a T cell with an antigen presenting cell (APC) in the presence of (i) a composition capable of upregulating expression of an endogenous Notch or Notch ligand in the APC and/or T cell and (ii) the allergen or antigen.

25. (New) The method according to any one of claims 21 to 24, wherein the composition comprises a substance capable of upregulating expression of Notch or a Notch ligand selected from polypeptides and fragments thereof, linear peptides, cyclic peptides, synthetic and natural compounds including low molecular weight organic or inorganic compounds.

26. (New) The method according to any one of claims 21 to 24, wherein the composition comprises a polypeptide selected from Noggin, Chordin, Follistatin, Xnr3, FGF and derivatives, fragments, variants and homologues thereof, and immunosuppressive cytokines, or a combination thereof.

A3 27. (New) The method according to claim 26, wherein the immunosuppressive cytokine is selected from IL-4, IL-10, IL-13, TGF- β and FLT3 ligand.

28. (New) The method according to any one of claims 21 to 24, wherein the Notch ligand is selected from Serrate, Delta and homologues thereof.

29. (New) The method according to any one of claims 21 to 24, wherein the APC is a dendritic cell.

30. (New) A method for producing a lymphocyte or APC having tolerance to an allergen or antigen, which method comprises incubating a lymphocyte or APC with a lymphocyte or APC produced by the method of any one of claims 21 to 24.

31. (New) A method for producing a T cell having tolerance to an allergen or antigen, which method comprises incubating a T cell with a cell produced by the method of any one of claims 21 to 24.

32. (New) A method for suppressing an immune response in a mammal to an allergen or antigen comprising incubating a lymphocyte or APC with (i) a composition capable of

upregulating expression of Serrate or Delta in the lymphocyte or APC and (ii) the allergen or antigen and administering the lymphocyte or APC to the mammal.

33. (New) A method for producing a lymphocyte or antigen presenting cell (APC) having tolerance to an allergen or antigen, which method comprises incubating a lymphocyte or APC with (i) a composition capable of upregulating expression of Serrate or Delta in the lymphocyte and/or APC and (ii) the allergen or antigen, wherein the lymphocyte is a T cell and the APC is a dendritic cell and wherein the composition comprises a polypeptide selected from the group consisting of Noggin, Chordin, Follistatin, Xnr3, FGF and immunosuppressive cytokines.

34. (New) The method of claim 33, wherein the allergen or antigen is selected from the group consisting of myelin basic protein, collagen, insulin, MHC antigens and Der p 1.
